Why the study?
Key knowledge gaps remain regarding mitochondrial network regulation and the limited clinical translation of targeted therapies in heart failure.
Design
Review
Key result
Mitochondrial dysfunction drives heart failure progression through metabolic reprogramming, calcium dysregulation, and ferroptosis, making multi-targeted mitochondrial regulation a promising therapeutic strategy.
Authors
Loading...
Mitochondrial-targeted therapies remain investigational in HFrEF; leaves open whether they will improve outcomes in randomized trials.
Mitochondrial dysfunction is a central event in heart failure pathogenesis, and targeting mitochondrial quality control and metabolic imbalances offers a promising approach for individualized treatment.
San et al. (2026) conducted a review in Heart failure. Mitochondrial dysfunction drives heart failure progression through metabolic reprogramming, calcium dysregulation, and ferroptosis, making multi-targeted mitochondrial regulation a promising therapeutic strategy.